Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 950 participants.
Also called NCT07684144
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 950 participants
- Sponsor
- Registry
-
NCT07684144 -
2025-524788-19-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Japan, Puerto Rico, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07684144. Randomized; double masking; primary purpose treatment. Start 2026-07-29 (actual); primary completion 2027-12-26 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Maridebart Cafraglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct07684144- Content hash
dcd70188a296bdd1c9352232ad1e635cf8836067f6562420766c7a85f95829ae